

# Benjamin A Steinberg, Mhs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4659867/publications.pdf>

Version: 2024-02-01

130  
papers

5,606  
citations

117625

34  
h-index

82547

72  
g-index

140  
all docs

140  
docs citations

140  
times ranked

8161  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Circulation</i> , 2012, 126, 65-75.	1.6	681
2	Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2006, 48, 438-445.	2.8	668
3	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2597-2604.	2.8	401
4	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	2.2	266
5	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494.	1.6	224
6	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. <i>JAMA Cardiology</i> , 2016, 1, 282.	6.1	182
7	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	2.7	161
8	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	143
9	Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 721-728.	1.6	132
10	Medical Therapies and Invasive Treatments for Coronary Artery Disease by Body Mass: The "Obesity Paradox" in the Get With The Guidelines Database. <i>American Journal of Cardiology</i> , 2007, 100, 1331-1335.	1.6	130
11	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 167, 735-742.e2.	2.7	120
12	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2018, 3, 1174.	6.1	111
13	Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons <sc>CAPS</sc> Care Atrial Fibrillation Registry. <i>Clinical Cardiology</i> , 2014, 37, 7-13.	1.8	105
14	Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. <i>Heart Rhythm</i> , 2018, 15, 651-657.	0.7	102
15	Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2013, 2, e000535.	3.7	92
16	Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. <i>American Heart Journal</i> , 2008, 156, 719-727.	2.7	82
17	High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1583-1594.	3.2	81
18	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	6.1	77

#	ARTICLE	IF	CITATIONS
19	Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 2005-2012.	1.6	73
20	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. <i>JACC: Heart Failure</i> , 2014, 2, 623-629.	4.1	72
21	Anticoagulation in atrial fibrillation. <i>BMJ, The</i> , 2014, 348, g2116-g2116.	6.0	68
22	Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2015, 33, 177-183.	2.5	67
23	Outcomes registry for better informed treatment of atrial fibrillation II: Rationale and design of the ORBIT-AF II registry. <i>American Heart Journal</i> , 2014, 168, 160-167.	2.7	62
24	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2013, 165, 622-629.	2.7	61
25	Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). <i>American Heart Journal</i> , 2017, 189, 40-47.	2.7	53
26	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
27	Heart rate is associated with progression of atrial fibrillation, independent of rhythm. <i>Heart</i> , 2015, 101, 894-899.	2.9	52
28	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020, 41, 1132-1140.	2.2	50
29	Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 213-221.	1.3	45
30	Cardiac conduction system disease after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2012, 164, 664-671.	2.7	43
31	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, e002031.	3.7	41
32	Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry). <i>American Journal of Cardiology</i> , 2007, 99, 1212-1215.	1.6	40
33	Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 119, 1017-1022.	1.6	36
34	Comparison of 2 Natural Language Processing Methods for Identification of Bleeding Among Critically Ill Patients. <i>JAMA Network Open</i> , 2018, 1, e183451.	5.9	36
35	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 221-229.	3.2	33
36	Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.6	33
	<i>Journal of Cardiology</i> , 2017, 119, 1590-1595.		

#	ARTICLE	IF	CITATIONS
37	Implementation of Real-Time Assessment of Patient-Reported Outcomes in a Heart Failure Clinic: A Feasibility Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 813-816.	1.7	33
38	Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	29
39	Is Coding for Myocardial Infarction More Accurate Now That Coding Descriptions Have Been Clarified to Distinguish ST-Elevation Myocardial Infarction from Non-ST Elevation Myocardial Infarction?. <i>American Journal of Cardiology</i> , 2008, 102, 513-517.	1.6	28
40	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	4.8	27
41	Magnetocardiogram Recordings in a Nonshielded Environment—Reproducibility and Ischemia Detection. <i>Annals of Noninvasive Electrocardiology</i> , 2005, 10, 152-160.	1.1	26
42	Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2017, 130, 449-456.	1.5	25
43	Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential. <i>American Journal of Cardiology</i> , 2007, 100, S27-S32.	1.6	24
44	Association of Wearable Device Use With Pulse Rate and Health Care Use in Adults With Atrial Fibrillation. <i>JAMA Network Open</i> , 2021, 4, e215821.	5.9	24
45	Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. <i>Heart Rhythm</i> , 2021, 18, 709-716.	0.7	24
46	Patient-Reported Outcomes in Atrial Fibrillation Research. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 599-605.	3.2	23
47	Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 957.	6.1	23
48	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. <i>Heart</i> , 2019, 105, heartjnl-2018-313642.	2.9	22
49	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. <i>American Heart Journal</i> , 2020, 223, 65-71.	2.7	22
50	Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, CIRCEP121007958.	4.8	20
51	Global outcomes of ST-elevation myocardial infarction: Comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. <i>American Heart Journal</i> , 2007, 154, 54-61.	2.7	19
52	Impact of Different Electronic Cohort Definitions to Identify Patients With Atrial Fibrillation From the Electronic Medical Record. <i>Journal of the American Heart Association</i> , 2020, 9, e014527.	3.7	19
53	Revisiting Rate versus Rhythm Control in Atrial Fibrillation—Timing Matters. <i>New England Journal of Medicine</i> , 2020, 383, 1383-1384.	27.0	18
54	Comparative Effectiveness of Pharmacotherapies for Prevention of Atrial Fibrillation Following Coronary Artery Bypass Surgery. <i>American Journal of Cardiology</i> , 2013, 112, 954-960.	1.6	17

#	ARTICLE	IF	CITATIONS
55	MODULES OVER $\mathbb{A}_n$ -TALE GROUPOID ALGEBRAS AS SHEAVES. <i>Journal of the Australian Mathematical Society</i> , 2014, 97, 418-429.	0.4	17
56	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 319.	6.1	17
57	Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. <i>Heart</i> , 2014, 100, 1871-1877.	2.9	16
58	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. <i>Heart</i> , 2020, 106, 358-364.	2.9	16
59	Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. <i>Europace</i> , 2020, 22, 368-374.	1.7	15
60	Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010304.	4.8	14
61	Safety of Bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. <i>International Journal of Cardiovascular Interventions</i> , 2005, 7, 88-92.	0.5	13
62	How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2016, 181, 145-152.	2.7	13
63	Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. <i>Clinical Cardiology</i> , 2017, 40, 746-751.	1.8	13
64	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1677-1683.	1.6	13
65	Screening for Atrial Fibrillation With a Wearable Device. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 139.	7.4	13
66	When Low-Risk Atrial Fibrillation Is Not So Low Risk. <i>JAMA Cardiology</i> , 2018, 3, 558.	6.1	12
67	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1384-1392.	3.2	12
68	Atrioventricular and ventricular-to-ventricular programming in patients with cardiac resynchronization therapy: results from ALTITUDE. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 279-287.	1.3	11
69	Long-Term Outcomes of Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2487-2489.	2.8	11
70	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP-AF risk scoring systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1440-1447.	1.2	11
71	Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011205.	3.7	11
72	Economics and outcomes of sotalol inpatient dosing approaches in patients with atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 333-342.	1.7	11

#	ARTICLE	IF	CITATIONS
73	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	2.7	10
74	Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace, 2014, 16, 1284-1290.	1.7	9
75	Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease. American Journal of Cardiology, 2014, 114, 716-722.	1.6	9
76	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58.	2.7	9
77	Are Statins Being Underdosed in Clinical Practice?. Critical Pathways in Cardiology, 2005, 4, 169-173.	0.5	8
78	How I use anticoagulation in atrial fibrillation. Blood, 2016, 128, 2891-2898.	1.4	8
79	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	2.7	8
80	Blanking period after radiofrequency ablation for atrial fibrillation guided by ablation lesion maturation based on serial MR imaging. Journal of Cardiovascular Electrophysiology, 2020, 31, 450-456.	1.7	8
81	Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. American Heart Journal, 2022, 243, 127-139.	2.7	8
82	Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician. Journal of Thrombosis and Thrombolysis, 2014, 37, 234-241.	2.1	7
83	Outcomes After Nonemergent Electrical Cardioversion for Atrial Arrhythmias. American Journal of Cardiology, 2015, 115, 1407-1414.	1.6	7
84	Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends in Cardiovascular Medicine, 2017, 27, 567-572.	4.9	7
85	Reproducibility of clinical late gadolinium enhancement magnetic resonance imaging in detecting left atrial scar after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2824-2832.	1.7	7
86	Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia, 2020, 36, 84-92.	1.2	7
87	High-density mapping of the tachycardia circuit in atrioventricular nodal reentrant tachycardia. Heart Rhythm Case Reports, 2016, 2, 451-453.	0.4	6
88	Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials. Heart Rhythm, 2017, 14, 1839-1848.	0.7	6
89	Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. Journal of Cardiovascular Electrophysiology, 2020, 31, 3187-3195.	1.7	6
90	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. American Heart Journal, 2022, 248, 42-52.	2.7	6

#	ARTICLE	IF	CITATIONS
91	Left Atrial Remodeling: Shape Before Size?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 760-761.	1.7	5
92	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 266-271.	1.6	5
93	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	2.2	5
94	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 153, 58-64.	1.6	5
95	Missed Diagnosis of the Diagnosis Codes. <i>Critical Pathways in Cardiology</i> , 2006, 5, 59-63.	0.5	4
96	Evaluation and Management of the Atrial Fibrillation Patient. <i>Critical Pathways in Cardiology</i> , 2013, 12, 107-115.	0.5	4
97	Social Media Influence Does Not Reflect Scholarly or Clinical Activity in Real Life. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008847.	4.8	4
98	Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. <i>Journal of Cardiac Failure</i> , 2022, 28, 13-20.	1.7	4
99	Year in Review in Cardiac Electrophysiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006648.	4.8	3
100	Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure. <i>Cardiology Clinics</i> , 2019, 37, 139-146.	2.2	3
101	Accuracy of Patient Identification of Electrocardiogram-Verified Atrial Arrhythmias. <i>JAMA Network Open</i> , 2020, 3, e205431.	5.9	3
102	Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. <i>American Heart Journal</i> , 2022, 244, 116-124.	2.7	3
103	Patient-reported outcomes and costs associated with vascular closure and same-day discharge following atrial fibrillation ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1737-1744.	1.7	3
104	An Annual, Prospective, International Study of Outpatients With Cardiovascular Disease or Risk Factors. <i>Critical Pathways in Cardiology</i> , 2007, 6, 72-75.	0.5	2
105	Treatment Pathways and Quality Improvement for Patients With Acute Myocardial Infarction at a Tertiary Care Center. <i>Critical Pathways in Cardiology</i> , 2012, 11, 77-80.	0.5	2
106	Call me maybe? The right time and place for BPAs in EHRs. <i>European Heart Journal</i> , 2020, 41, 1097-1099.	2.2	2
107	Year in Review in Cardiac Electrophysiology. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007142.	4.8	2
108	Development of a Portable Tool to Identify Patients With Atrial Fibrillation Using Clinical Notes From the Electronic Medical Record. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006516.	2.2	2



#	ARTICLE	IF	CITATIONS
109	Clinical strokes in atrial fibrillation: the tip of the iceberg. <i>European Heart Journal</i> , 2022, 43, 2136-2138.	2.2	2
110	Shorter distance between the esophagus and the left atrium is associated with higher rates of esophageal thermal injury after radiofrequency ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1460-1471.	1.7	2
111	Refined bleeding estimates in adults starting anticoagulants. <i>BMJ, The</i> , 2014, 349, g4800-g4800.	6.0	1
112	Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive procedures. <i>Evidence-Based Medicine</i> , 2015, 20, 200-200.	0.6	1
113	Return on Investment in Implantable Devices. <i>JACC: Heart Failure</i> , 2017, 5, 213-215.	4.1	1
114	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). <i>American Journal of Cardiology</i> , 2020, 132, 66-71.	1.6	1
115	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008274.	3.9	1
116	Limitations of manufacturer-recommended remote monitoring in the St. Jude Assurity/Endurity battery recall. <i>HeartRhythm Case Reports</i> , 2021, 7, 791-794.	0.4	1
117	Short-term natural course of esophageal thermal injury after ablation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1450-1459.	1.7	1
118	Dose-adjusted warfarin: writing the prescription is only the beginning. <i>Journal of Electrocardiology</i> , 2013, 46, 51-53.	0.9	0
119	Risk assessment in atrial fibrillation: not all factors are created equal. <i>Europace</i> , 2014, 16, 156-158.	1.7	0
120	Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation. <i>Evidence-Based Medicine</i> , 2014, 19, 182-182.	0.6	0
121	ASSESSMENT OF STROKE RISK IN ATRIAL FIBRILLATION: PHYSICIAN ESTIMATE VERSUS CHADS2 RISK SCORE: RESULTS FROM ORBIT-AF. <i>Journal of the American College of Cardiology</i> , 2014, 63, A357.	2.8	0
122	Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital. <i>Europace</i> , 2016, 18, 1117-1118.	1.7	0
123	Preventing heart failure in atrial fibrillation: In the middle of difficulty lies opportunity. <i>Heart Rhythm</i> , 2017, 14, 799-800.	0.7	0
124	VALIDATION OF AN ELECTRONIC TOOL TO CALCULATE CHA2DS2-VASC SCORES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 496.	2.8	0
125	PATIENT HEALTH STATUS TRAJECTORIES IN HEART FAILURE WITH RECOVERED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 970.	2.8	0
126	NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 547.	2.8	0



#	ARTICLE	IF	CITATIONS
127	Atrial Fibrillation and Heart Failure: In This Challenge Lies Opportunity. <i>Cardiology Clinics</i> , 2019, 37, xiii.	2.2	0
128	Impact of Catheter Ablation on Stroke, Cognitive Decline and Dementia. <i>Arrhythmia and Electrophysiology Review</i> , 2021, 10, 205-210.	2.4	0
129	Clinical Investigations Bimodal Distribution of Atrial Fibrillation Burden in 3 Distinct Cohorts: What is â€˜Paroxysmalâ€™ Atrial Fibrillation?. <i>American Heart Journal</i> , 2021, 244, 149-149.	2.7	0
130	Measuring â€˜Symptomaticâ€™ Atrial Fibrillation: One View is No View. <i>Heart Rhythm</i> , 2022, , .	0.7	0